What is the clinical evidence from this study?

Study design: Observational. Population: Valvular heart disease requiring multiple valve replacement (n=76). Intervention: Multiple valve replacement with pericardial xenografts. Primary outcome: Early deaths.

What question did this study set out to answer?

To assess the clinical outcomes, thromboembolic incidence, and hemodynamic performance of multiple valve replacement using pericardial xenografts without routine long-term anticoagulation.

November 1, 1980HeartOpen Access

Multiple valve replacement with pericardial xenograft. Clinical and haemodynamic study.

View Full Paper

Ask AI

Bookmark

Key result

Multiple valve replacement with pericardial xenografts resulted in 10.5% early and 3.9% late mortality, with an estimated 94.7% survival at 3.5 years among hospital survivors.

Population

76 patients undergoing multiple valve replacement

Design

Case_series

Follow-up

up to 3.5 years

Authors

ATAnand P. TandonThe Honourable Society of Lincoln's Inn WWW WhitakerUniformed Services University of the Health Sciences MIM. I. IonescuLeeds General Infirmary

Discussion

Member takes

Implication

May offer anticoagulation-free multiple valve replacement option; leaves open need for prospective comparative trials.

Key Points

To assess the clinical outcomes, thromboembolic incidence, and hemodynamic performance of multiple valve replacement using pericardial xenografts without routine long-term anticoagulation.
Evaluated 76 patients who underwent multiple valve replacement with pericardial xenografts (sizes 17 to 31) without long-term anticoagulant therapy.
Performed hemodynamic assessments in 7 patients between 8 and 21 months postoperatively to measure transvalvular gradients and calculate valve surface areas.
Early mortality was 10.5% and late mortality was 3.9%, with an actuarially predicted survival of 94.7 ± 3.9% for hospital survivors at 3.5 years.
No thrombotic valve obstruction or mechanical dysfunction occurred, with systemic embolism observed in 1 patient (0.95 episodes per 100 patient-years).
Hemodynamic testing revealed negligible aortic gradients, small mitral and tricuspid gradients, and calculated surface areas of 1.0–1.4 cm² (aortic), 1.7–2.1 cm² (mitral), and 2.0–2.4 cm² (tricuspid).

Study Design

Type

Observational (n=76)

Structured PICO

Population

76 patients undergoing multiple valve replacement with pericardial xenografts, followed for up to 3.5 years.

Exposure

Multiple valve replacement with pericardial xenografts (sizes 17 to 31) without long-term anticoagulants

Outcome

Early and late deathshard clinical

Multiple valve replacement with pericardial xenografts demonstrates acceptable mid-term survival, good haemodynamic performance, and low thromboembolic risk without the need for long-term anticoagulation.

Cite This Study

Tandon et al. (1980) conducted an observational in Valvular heart disease requiring multiple valve replacement (n=76). Multiple valve replacement with pericardial xenografts was evaluated on Early deaths. Multiple valve replacement with pericardial xenografts resulted in 10.5% early and 3.9% late mortality, with an estimated 94.7% survival at 3.5 years among hospital survivors.

synapsesocial.com/papers/6aa4661d03e52771fd25691d https://doi.org/10.1136/hrt.44.5.534

Topics

Valvular heart disease

View Full Paper

Ask AI

Bookmark

November 1, 1980HeartOpen Access

Multiple valve replacement with pericardial xenograft. Clinical and haemodynamic study.

View Full Paper

Ask AI

Bookmark

Key result

Multiple valve replacement with pericardial xenografts resulted in 10.5% early and 3.9% late mortality, with an estimated 94.7% survival at 3.5 years among hospital survivors.

Population

76 patients undergoing multiple valve replacement

Design

Case_series

Follow-up

up to 3.5 years

Authors

ATAnand P. TandonThe Honourable Society of Lincoln's Inn WWW WhitakerUniformed Services University of the Health Sciences MIM. I. IonescuLeeds General Infirmary

Discussion

Member takes

Implication

May offer anticoagulation-free multiple valve replacement option; leaves open need for prospective comparative trials.

Key Points

To assess the clinical outcomes, thromboembolic incidence, and hemodynamic performance of multiple valve replacement using pericardial xenografts without routine long-term anticoagulation.
Evaluated 76 patients who underwent multiple valve replacement with pericardial xenografts (sizes 17 to 31) without long-term anticoagulant therapy.
Performed hemodynamic assessments in 7 patients between 8 and 21 months postoperatively to measure transvalvular gradients and calculate valve surface areas.
Early mortality was 10.5% and late mortality was 3.9%, with an actuarially predicted survival of 94.7 ± 3.9% for hospital survivors at 3.5 years.
No thrombotic valve obstruction or mechanical dysfunction occurred, with systemic embolism observed in 1 patient (0.95 episodes per 100 patient-years).
Hemodynamic testing revealed negligible aortic gradients, small mitral and tricuspid gradients, and calculated surface areas of 1.0–1.4 cm² (aortic), 1.7–2.1 cm² (mitral), and 2.0–2.4 cm² (tricuspid).

Study Design

Type

Observational (n=76)

Structured PICO

Population

76 patients undergoing multiple valve replacement with pericardial xenografts, followed for up to 3.5 years.

Exposure

Multiple valve replacement with pericardial xenografts (sizes 17 to 31) without long-term anticoagulants

Outcome

Early and late deathshard clinical

Cite This Study

synapsesocial.com/papers/6aa4661d03e52771fd25691d https://doi.org/10.1136/hrt.44.5.534

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Topics

Valvular heart disease

View Full Paper

Ask AI

Bookmark